Anaplastic Large Cell Lymphoma Arising in a Silicone Breast Implant Capsule: A Case Report and Review of the Literature-Reference-Cited by-同舟云学术

Anaplastic Large Cell Lymphoma Arising in a Silicone Breast Implant Capsule: A Case Report and Review of the Literature

Published:2003-03-01 Issue:3 Volume:127 Page:e115-e118
ISSN:1543-2165
Container-title:Archives of Pathology & Laboratory Medicine
language:en
Short-container-title:

Author:

Sahoo Sunati¹,Rosen Paul P.¹,Feddersen Richard M.¹,Viswanatha David S.¹,Clark Douglas A.¹,Chadburn Amy¹

Affiliation:

1. From the Department of Pathology, New York Presbyterian Hospital-Weill Cornell Center, New York, NY (Drs Sahoo, Rosen, and Chadburn); the Department of Pathology, University of New Mexico School of Medicine, Albuquerque (Drs Feddersen and Viswanatha); and New Mexico Oncology Hematology Consultants, Albuquerque (Dr Clark)

Abstract

Abstract Anaplastic large cell lymphoma is a rare type of primary breast lymphoma. We report a case of anaplastic large cell lymphoma, T-cell phenotype, occurring in the periprosthetic capsule of a silicone breast prosthesis 9 years after implantation for augmentation mammoplasty. This case is unique for its unusual presentation.

Publisher

Archives of Pathology and Laboratory Medicine

Subject

Medical Laboratory Technology,General Medicine,Pathology and Forensic Medicine

Link

http://meridian.allenpress.com/aplm/article-pdf/127/3/e115/2730231/0003-9985(2003)127_e115_alclai_2_0_co_2.pdf

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current State of Evidence-Based Long-Term Monitoring Protocols for Breast Plastic Surgery Patients;Annals of Surgical Oncology;2024-08-05

2. Implant replacement and anaplastic large cell lymphoma associated with breast implants: a quantitative analysis;Frontiers in Oncology;2023-10-19

3. The plasticity of biocompatibility;Biomaterials;2023-05

4. Breast lymphomas, breast implants and capsules The timeline of BIA-ALCL with respect to surgical consent: the UK perspective;JPRAS Open;2022-12

5. CD30+ Lymphoproliferative Disorders as Potential Candidates for CD30-Targeted Therapies;Archives of Pathology & Laboratory Medicine;2022-03-17